Recent Company News

• 08:50 PM ET Feb 11, 2026
  

  NICE recommends Merck's Zejula for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy ($119.31, 0.00)

• 10:08 AM ET Feb 11, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (477 total)

• 10:02 AM ET Feb 10, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (248 total)

• 08:30 AM ET Feb 10, 2026
  

  Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

• 03:07 AM ET Feb 10, 2026
  

  FDA accepts NDA and grants priority review to Takeda Pharmaceutical's oveporexton (TAK-861) for narcolepsy type 1 (¥5581.0000, 0)

• 10:27 PM ET Feb 08, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (269 total)

• 10:07 PM ET Feb 08, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (571 total)

• 09:53 AM ET Feb 05, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (208 total)

• 11:10 PM ET Feb 04, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (187 total)

• 10:20 PM ET Feb 04, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (393 total)